LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

Main Article Content

Jassada Buaboonnam
Chayamon Takpradit
Vip Viprakasit
Nattee Narkbunnam
Nassawee Vathana
Kamon Phuakpet
Kleebsabai Sanpakit
Bunchoo Pongtanakul

Keywords

deferasirox, Iron chelation, Iron Overload, Thalassemia

Abstract

Background: Patients with transfusion-dependent thalassemia (TDT) risk iron overload and require iron chelation therapy. Salvage therapy is warranted for patients demonstrating poor chelation responses.


Patients and methods: We retrospectively studied the serum-ferritin (SF) and liver-iron-concentration (LIC) outcomes of patients with TDT treated with twice-daily dosing of deferasirox (TDD-DFX) for > 24 months, after failing to respond to once-daily deferasirox (OD-DFX).


Results: We enrolled 22 patients (14 males and 8 females; median age, 9.2 [3–15.5] years). The median erythron transfusion was 216 (206–277) ml/kg/year. The median TDD-DFX treatment period was 30 (24–35) months. Before initiating TDD-DFX, the median SF level was 2,486 (1,562–8,183) ng/ml, while the median LIC was 6.5 (3.2–19) mg/g dry wt. There were 18 responders (81.8%) and 4 nonresponders. The median SF-level change was -724 (-4 916 to 1,490) ng/mL. The median LIC change was -2.14 (-13.7 to 6.8) mg/g dry wt. The 1-year and end-of-study SF levels and LICs were statistically significant (SF, P = 0.006/0.005; and LIC, 0.006/0.005, respectively). There were no treatment interruptions secondary to adverse events. In the follow-up of the TDD-DFX-responder group, 11 of the 18 had a reduced dose, whereas the remaining 7 continued with the same dose.


Conclusions: TDD-DFX appears to be an alternative treatment approach for patients refractory to OD-DFX, with a favorable long-term safety profile. Further studies with larger groups and pharmacogenetic analyses of inadequate responders are warranted to better determine the efficacy and safety profile of TDD-DFX.

Downloads

Download data is not yet available.


Abstract 549
PDF Downloads 243
HTML Downloads 78

References

[1] Fucharoen S, Winichagoon P. Thalassemia in SouthEast Asia: problems and strategy for prevention and control. Southeast Asian J Trop Med Public Health. 1992;23:647-55
[2] Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118:884-93. doi:10.1182/blood-2010-11-316646

[3] Chang HH, Lu MY, Liao YM, et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr Blood Cancer. 2011;56:420-4. doi:10.1002/pbc.22826

[4] Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97:842-8. doi:10.3324/haematol.2011.049957

[5] Pongtanakul B, Viprakasit V. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood Cells Mol Dis. 2013;51:96-7. doi:10.1016/j.bcmd.2013.03.004

[6] Saiviroonporn P, Viprakasit V, Maneesai A, et al. Inter-site validations of the Pixel-Wise method for cardiac T2* analysis in transfusion-dependent Thai thalassemia patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2012;95 Suppl 2:S165-72
[7] Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114:4009-13. doi:10.1182/blood-2009-05-222729

[8] Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013;88:251-60. doi:10.1002/ajh.23386

[9] Takpradit C, Viprakasit V. Using of deferasirox and deferoxamine in refractory iron overload thalassemia. 2021;63:404-9. doi:10.1111/ped.14444

[10] Otto-Duessel M, Aguilar M, Nick H, Moats R, Wood JC. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Experimental hematology. 2007;35:1069-73. doi:10.1016/j.exphem.2007.04.001

[11] Salehifar E, Karami H, Kosaryan M, et al. Efficacy of Oral Deferasirox by Twice-daily Dosing in Patients with Transfusion-dependent Beta Thalassemia. Journal of Mazandaran University of Medical Sciences. 2015;25:1-8
[12] Gumruk F, Unal S, Bayhan T, Hazirolan T, Tuncer AM, Cetin M. Twice Daily Use of Deferasirox Is More Effective in Decreasing Serum Ferritin. Blood. 2014;124:2675-. doi:10.1182/blood.V124.21.2675.2675

[13] Karimi M, Haghpanah S, Bahoush G, et al. Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. J Pediatr Hematol Oncol. 2020;42:23-6. doi:10.1097/mph.0000000000001596